INSIGHTS ON DRUG DEVELOPMENT
-
![Lab Software GettyImages-1180547354]( "LC-UV-Based Synthetic Peptide Impurity Tracking And Reporting")
LC-UV-Based Synthetic Peptide Impurity Tracking And ReportingExplore a UPLC-UV method using Empower 3 Software to assess synthetic peptide purity. Learn how integrated tools streamline impurity tracking, data reporting, and compliance in peptide analysis workflows.
-
![Daniele Vigo]( "Optimizing Yield, Purity, And Scalability In A Cost-Effective Manner During Process Development")
Optimizing Yield, Purity, And Scalability In A Cost-Effective Manner During Process DevelopmentDaniele Vigo, Assistant Director at Cambrex Milan, on getting yield, purity, and scalability right without burning through the budget.
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Optimization And Scale-Up Of A Plasmid DNA Production Process")
Optimization And Scale-Up Of A Plasmid DNA Production ProcessOptimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.
-
![GettyImages-1214921728-lab-glassware-beaker-vial-test-tube]( "Patented Process For Intermediates Useful For Deucravacitinib")
Patented Process For Intermediates Useful For DeucravacitinibDiscover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.
-
EMA Support For SMEs Through Scientific Advice And Early Dialogue5/6/2026
Discover how early engagement with European regulators helps smaller drug developers reduce uncertainty, clarify requirements, and de‑risk innovative programs through early dialogue.
-
Imagine The Future: An Enhanced Oligonucleotide Synthesis Process2/9/2026
Gain practical guidance for improving oligo quality, see how an advanced synthesis platform supports production, and explore a software interface designed to make daily operations more intuitive.
-
Development Of Separation Methods for GLP-1 Synthetic Peptides6/27/2025
Peptides offer precise, low-cost therapeutic potential, especially in GLP-1 drugs for diabetes and weight loss. A new HPLC-UV/MS method ensures consistent quality and analysis of these compounds.
-
Making Accelerated Predictive Stability Studies Even Faster With Software6/18/2026
Drug stability depends on environmental conditions, but testing every scenario experimentally isn’t practical. Accelerated predictive stability uses mathematical modeling to forecast degradation, helping scientists make faster, data-driven decisions early in development.
-
Biopharma Production And Quality Control With Electrophoresis2/20/2025
Discover how Kaneka Eurogentec, a leading provider of custom DNA synthesis and molecular biology services, enhanced their fragment analysis to achieve higher efficiency and accuracy in their workflows.
DRUG DEVELOPMENT SOLUTIONS
-
![adare]( "A Technology-Driven CDMO Delivering Integrated End-To-End Services")
Explore this interactive PDF with information about technologies & end-to-end integrated CDMO services provided by Adare Pharma Solutions.
-
![mPredict™ Co-Crystal Prediction Service]( "Co-Crystal Prediction Service")
AI-driven co-crystal prediction accelerates solubility optimization by identifying ideal co-formers in days without needing the drug substance. Learn how to save time, reduce costs, and boost formulation success.
-
MaxPeak™ Premier Columns utilize MaxPeak High Performance Surfaces that are designed to increase analyte recovery, sensitivity, and reproducibility by minimizing analyte/surface interactions that can lead to sample losses.
-
![LSC-iCELLis-Family]( "iCELLis™ Single-Use Fixed-Bed Bioreactor Systems")
The iCELLis™ bioreactor system is an automated, single-use, fixed-bed bioreactor that provides excellent cell growth conditions for adherent cells.
-
![GettyImages-1327977866-cell-culture-sample-laboratory]( "Powering Production Of Viral Vector-Based Therapies")
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.
